Completed PHASE3 INTERVENTIONAL 2-arm NCT01837251

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

A Prospective Randomized Phase III Trial of Carboplatin/Gemcitabine/Bevacizumab vs. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Sponsor: AGO Research GmbH

Conditions Recurrent Platinum-sensitive Ovarian Cancer

Interventions Bevacizumab Carboplatin PLD

Updated 10 times since 2017 Last updated: Jul 8, 2021 Started: May 31, 2013 Primary completion: Jan 31, 2021 Completion: Jan 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Recurrent Platinum-sensitive Ovarian Cancer and is currently completed. AGO Research GmbH leads this study, which shows 10 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Sep 2021 — Jul 2024 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Jan 2021 — Sep 2021 [monthly]

Unknown Status PHASE3

Status: Active Not Recruiting → Unknown Status

▶ Show 5 earlier versions

Nov 2019 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
Jan 2019 — Nov 2019 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Jan 2019 [monthly]

Active Not Recruiting PHASE3
Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AGO Research GmbH
ARCAGY/ GINECO GROUP
Arbeitsgemeinschaft Gynaekologische Onkologie Austria
Australia New Zealand Gynaecological Oncology Group
Scottish Gynaecological Cancer Study Group

Data source: AGO Research GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Altötting, Germany , Amberg, Germany , Angers, France , Aschaffenburg, Germany , Augsburg, Germany , Avignon, France , Bad Homburg, Germany , Bangor, United Kingdom , Bankstown, Australia , Berlin, Germany and 155 more locations